How Much Semaglutide to Take: The Evidence-Based Dosing Protocol for Weight Loss and Diabetes

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Standard weight-loss semaglutide dosing starts at 0.25 mg weekly and escalates every 4 weeks to a maximum of 2.4 mg, following the STEP trial protocol that produced 15% average weight loss
• Type 2 diabetes dosing follows a separate schedule, maxing at 1 mg weekly (Ozempic) or 2 mg weekly (Wegovy off-label), with different efficacy targets
• Your maintenance dose is the lowest dose that produces consistent 1-2 pound weekly weight loss without intolerable side effects, not automatically the maximum dose
• Compounded semaglutide follows identical titration schedules to brand-name products but requires precise measurement and reconstitution technique

Direct answer (40-60 words)

For weight loss, start semaglutide at 0.25 mg weekly for 4 weeks, then escalate to 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg, spending 4 weeks at each dose. For type 2 diabetes, the standard maximum is 1 mg weekly. Your maintenance dose is the lowest effective dose, not necessarily the maximum.

Table of contents

1. The two different dosing protocols: weight loss vs diabetes
2. The standard weight-loss titration schedule (STEP protocol)
3. The diabetes titration schedule (SUSTAIN protocol)
4. What most articles get wrong about "maximum dose"
5. How to know when to escalate vs stay at your current dose
6. The dose-response curve: does higher always mean better?
7. Compounded semaglutide dosing and measurement
8. When to dose more frequently than weekly
9. The FormBlends Dose Decision Framework
10. Special populations: dosing adjustments for age, kidney function, and prior bariatric surgery
11. What to do if you miss a dose
12. When lower doses work better than higher doses
13. FAQ
14. Sources

The two different dosing protocols: weight loss vs diabetes

Semaglutide has two distinct FDA-approved dosing protocols because it treats two different conditions with different endpoints.

Weight-loss dosing (Wegovy protocol):

• Starting dose: 0.25 mg weekly
• Maximum dose: 2.4 mg weekly
• Titration period: 20 weeks
• Goal: 15% or greater total body weight loss over 68 weeks

Type 2 diabetes dosing (Ozempic protocol):

• Starting dose: 0.25 mg weekly
• Standard maximum: 1 mg weekly
• Extended maximum: 2 mg weekly (approved 2022)
• Titration period: 8 to 12 weeks
• Goal: HbA1c reduction of 1.5 to 2 percentage points

The confusion happens because the same molecule (semaglutide) is sold under two brand names with different dosing instructions. Wegovy is FDA-approved for obesity. Ozempic is FDA-approved for type 2 diabetes but frequently prescribed off-label for weight loss at doses up to 2 mg.

Compounded semaglutide doesn't carry brand-name distinctions. Your provider prescribes a specific dose and titration schedule based on your treatment goal. Most compounding pharmacies default to the weight-loss protocol because that's what most patients request, but the diabetes protocol is equally valid if glycemic control is the primary endpoint.

The protocols aren't interchangeable. Using the diabetes protocol for weight loss typically produces suboptimal results. The STEP-1 trial (Wilding et al., New England Journal of Medicine, 2021) showed that patients who stopped at 1 mg lost an average of 10.9% body weight vs 15.8% at 2.4 mg. That 5-percentage-point difference is clinically meaningful for most patients.

The standard weight-loss titration schedule (STEP protocol)

This is the schedule used in the STEP clinical trial program, which enrolled 4,567 patients across five trials and established semaglutide as the most effective GLP-1 medication for weight loss.

Week	Dose	Duration	Purpose
0-3	0.25 mg	4 weeks	GI adaptation, assess tolerability
4-7	0.5 mg	4 weeks	First therapeutic dose, early weight loss
8-11	1 mg	4 weeks	Moderate therapeutic dose
12-15	1.7 mg	4 weeks	High therapeutic dose
16-19	2.4 mg	4 weeks	Maximum dose
20+	2.4 mg	Ongoing	Maintenance

The 4-week intervals are not arbitrary. Semaglutide has a half-life of 7 days, which means it takes roughly 4 to 5 weeks to reach steady-state concentration at any given dose. Escalating faster than every 4 weeks means you're changing the dose before your body has fully adapted to the previous one, which increases nausea and vomiting risk without improving weight-loss outcomes.

The STEP-1 trial data shows the dose-response relationship clearly:

• 0.25 mg: Minimal weight loss (2-3% over 68 weeks), used only for adaptation
• 0.5 mg: 6.4% average weight loss
• 1 mg: 10.9% average weight loss
• 1.7 mg: 13.8% average weight loss
• 2.4 mg: 15.8% average weight loss

Each escalation produces incremental benefit, but the jumps get smaller as you approach maximum dose. The difference between 0.5 mg and 1 mg is 4.5 percentage points. The difference between 1.7 mg and 2.4 mg is 2 percentage points.

The diabetes titration schedule (SUSTAIN protocol)

The SUSTAIN trial program (Sorli et al., Diabetes Care, 2017) used a faster titration schedule because the primary endpoint was glycemic control, not weight loss, and HbA1c responds faster than adipose tissue.

Week	Dose	Duration
0-3	0.25 mg	4 weeks
4-7	0.5 mg	4 weeks
8+	1 mg	Ongoing

Optional escalation to 2 mg if HbA1c remains above target:

Week	Dose	Duration
8-11	1 mg	4 weeks
12+	2 mg	Ongoing

The diabetes protocol stops at 1 mg for most patients because that dose produces near-maximal HbA1c reduction (1.8 percentage points on average). The jump from 1 mg to 2 mg adds only 0.3 percentage points of additional HbA1c reduction but doubles the nausea rate.

For patients using semaglutide primarily for diabetes with weight loss as a secondary goal, the diabetes protocol is appropriate. For patients using it primarily for weight loss who happen to have diabetes, the weight-loss protocol is appropriate. The distinction matters because the slower titration to 2.4 mg produces better tolerability and lower discontinuation rates.

What most articles get wrong about "maximum dose"

The most common error in semaglutide dosing content is treating 2.4 mg as a universal target that every patient should reach. This is wrong for three reasons.

First, the clinical trial data doesn't support it. In STEP-1, 32% of patients discontinued treatment before reaching 2.4 mg, most commonly due to gastrointestinal side effects. Of those who reached 2.4 mg, 8% later reduced their dose due to tolerability issues. The "successful" cohort in the trial includes patients who maintained at 1 mg, 1.7 mg, and 2.4 mg.

Second, individual dose-response curves vary widely. A subset of patients (roughly 15-20% based on STEP trial subgroup analysis) achieve 15% or greater weight loss at 1 mg or 1.7 mg. For these patients, escalating to 2.4 mg adds side-effect risk without meaningful benefit. The goal is the lowest effective dose, not the highest tolerable dose.

Third, maintenance dose often differs from titration dose. Many patients reach 2.4 mg, maintain for 12 to 24 weeks, then reduce to 1.7 mg or 1 mg for long-term maintenance once they've achieved their weight-loss goal. The maintenance dose is the dose that prevents weight regain, which is often lower than the dose that produced initial weight loss.

The correct framing: 2.4 mg is the maximum studied dose, not the target dose. Your target dose is the dose that produces 1 to 2 pounds of weekly weight loss (during active weight-loss phase) or stable weight (during maintenance phase) without intolerable side effects.

How to know when to escalate vs stay at your current dose

The decision to escalate follows a simple three-part test. If all three conditions are true, escalate. If any one is false, stay at your current dose.

Condition 1: You've been at the current dose for at least 4 weeks. Semaglutide takes 4 to 5 weeks to reach steady state. Escalating sooner means you're chasing a moving target. The exception: if you have severe intolerable side effects in week 1 or 2, you may need to reduce dose or pause treatment, not escalate.

Condition 2: Side effects are mild or absent. Mild means occasional nausea that doesn't interfere with daily activities, manageable constipation, or transient fatigue. Moderate to severe means vomiting more than once per week, inability to eat normal meals, or persistent symptoms that affect work or sleep. If side effects are moderate to severe, stay at current dose for another 4 weeks or reduce dose.

Condition 3: Weight loss has plateaued below your goal. Plateaued means less than 0.5 pounds per week average over the past 4 weeks. If you're still losing 1 to 2 pounds per week, there's no reason to escalate. The current dose is working. If you've reached your goal weight, you're in maintenance phase and should not escalate.

The most common escalation error is condition 3 violation. Patients losing 1.5 pounds per week at 1 mg escalate to 1.7 mg because "the protocol says to." The protocol is a framework, not a mandate. If the current dose is producing the desired outcome, stay there.

The dose-response curve: does higher always mean better?

No. The relationship between semaglutide dose and weight loss is logarithmic, not linear. Each dose increase produces smaller incremental benefit than the previous one.

Here's the incremental weight loss per dose escalation from STEP-1 data:

Dose increase	Additional weight loss
0.25 mg → 0.5 mg	+4.1 percentage points
0.5 mg → 1 mg	+4.5 percentage points
1 mg → 1.7 mg	+2.9 percentage points
1.7 mg → 2.4 mg	+2.0 percentage points

The curve flattens as you approach 2.4 mg. The jump from 0.5 mg to 1 mg produces more than twice the benefit of the jump from 1.7 mg to 2.4 mg.

Meanwhile, side-effect rates increase linearly or faster:

Dose	Nausea rate	Discontinuation due to GI side effects
0.5 mg	22%	2.4%
1 mg	28%	4.1%
1.7 mg	34%	5.8%
2.4 mg	44%	7.0%

The risk-benefit ratio gets worse as you escalate. For some patients, 1.7 mg is the sweet spot: 87% of the weight loss you'd get at 2.4 mg with 49% lower nausea rate.

This is why the FormBlends clinical pattern across compounded semaglutide patients shows a bimodal maintenance dose distribution. About 40% maintain at 2.4 mg, 35% maintain at 1.7 mg, 20% maintain at 1 mg, and 5% maintain at lower doses or discontinue. The patients at 1.7 mg aren't "failing to reach maximum dose." They've found their optimal dose.

Compounded semaglutide dosing and measurement

Compounded semaglutide typically comes as a lyophilized powder that you or your provider reconstitutes with bacteriostatic water. The final concentration determines how much liquid volume equals your prescribed dose.

Common compounding concentrations:

Vial size	Semaglutide amount	Bacteriostatic water	Final concentration	Volume for 0.5 mg dose
2 mL	5 mg	2 mL	2.5 mg/mL	0.2 mL
3 mL	5 mg	3 mL	1.67 mg/mL	0.3 mL
5 mL	10 mg	5 mL	2 mg/mL	0.25 mL

The concentration varies by compounding pharmacy. Your prescription should specify both the dose in milligrams (e.g., "0.5 mg") and the volume to inject (e.g., "0.2 mL"). If it doesn't, contact your provider before injecting.

The measurement error problem: Insulin syringes are marked in units (0.01 mL increments) or half-units (0.005 mL increments). A 0.05 mL measurement error at 2.5 mg/mL concentration means a 0.125 mg dosing error, which is 25% of a 0.5 mg dose. This matters.

Use a 0.5 mL or 1 mL insulin syringe with half-unit markings for doses below 1 mg. Use a 1 mL syringe with unit markings for doses at or above 1 mg. Draw to the exact line. If you're between lines, go to the lower line (slight underdosing is safer than overdosing).

Compounded semaglutide follows the same titration schedules as brand-name products. The molecule is identical. The pharmacokinetics are identical. The only difference is you're responsible for accurate measurement instead of using a pre-filled pen.

When to dose more frequently than weekly

Standard semaglutide dosing is once weekly. The 7-day half-life means blood levels stay relatively stable between doses. Some patients ask about splitting the weekly dose into two or three smaller doses to reduce side effects.

The published data on split dosing is limited. One small study (Nauck et al., Diabetes, Obesity and Metabolism, 2016) compared once-weekly semaglutide to twice-weekly half-doses and found no difference in efficacy but slightly lower nausea rates in the split-dose group. The study was underpowered (N = 58) and hasn't been replicated.

The theoretical argument for split dosing: GLP-1 receptor activation is dose-dependent. A single 1 mg injection produces a sharp peak in receptor activation in the first 24 to 48 hours, which is when nausea is worst. Splitting to 0.5 mg twice weekly produces two smaller peaks, potentially reducing peak-related side effects.

The argument against: convenience and adherence. Twice-weekly dosing doubles the number of injections, which increases the chance of missed doses and reduces long-term adherence. The STEP trials used once-weekly dosing, so that's the evidence-based standard.

When split dosing might make sense:

• Severe nausea at standard weekly doses that doesn't resolve after 4+ weeks
• History of severe motion sickness or hyperemesis gravidarum (suggests high susceptibility to GLP-1 nausea)
• Prior failed attempt at weekly dosing due to intolerable side effects

If you and your provider decide to try split dosing, the protocol is straightforward: take half your weekly dose every 3 to 4 days. A 1 mg weekly dose becomes 0.5 mg every 3.5 days. Track symptoms for 4 weeks and compare to your experience on weekly dosing.

The FormBlends Dose Decision Framework

This is a structured decision tree for the most common dosing questions patients face during titration. Use it at each 4-week checkpoint.

Decision point 1: Should I escalate to the next dose?

Start here. Answer yes or no to each question:

• Have I been at my current dose for at least 4 weeks? (If no, stay at current dose)
• Are my side effects mild or absent? (If no, stay at current dose)
• Am I still losing less than 0.5 pounds per week on average? (If no, stay at current dose)
• Am I below my goal weight? (If no, you're in maintenance mode, stay at current dose)

If yes to all four, escalate. If no to any one, stay at current dose for another 4 weeks and reassess.

Decision point 2: Should I reduce my dose?

Answer yes or no:

• Am I experiencing moderate to severe nausea, vomiting, or other GI symptoms that interfere with daily life? (If yes, reduce)
• Have symptoms persisted for more than 2 weeks at the current dose? (If yes, reduce)
• Am I losing more than 2% of body weight per week? (If yes, reduce or hold)

If yes to any one, reduce to the previous dose. If symptoms don't improve within 2 weeks at the lower dose, contact your provider.

Decision point 3: Should I stay at my current dose long-term?

Answer yes or no:

• Am I losing 1 to 2 pounds per week consistently? (If yes, stay)
• Have I reached my goal weight and maintained it for 4+ weeks? (If yes, stay)
• Are side effects minimal? (If yes, stay)

If yes to any one, your current dose is your maintenance dose. You don't need to escalate further.

[Diagram suggestion: Flowchart with three decision diamonds (escalate/reduce/maintain) and branching paths leading to action boxes. Use green for "escalate," yellow for "stay," and red for "reduce."]

The framework is designed to prevent the two most common dosing errors: escalating too fast when side effects are still present, and escalating unnecessarily when the current dose is already working.

Special populations: dosing adjustments for age, kidney function, and prior bariatric surgery

Age over 65: The STEP-1 trial included 12% of patients over age 65. Subgroup analysis showed similar weight-loss outcomes but slightly higher rates of nausea and diarrhea in older adults. The FDA label for Wegovy doesn't recommend dose adjustment based on age alone, but clinical practice often uses a more conservative titration schedule: 6 weeks per dose tier instead of 4 weeks for patients over 70.

Kidney disease: Semaglutide is not renally cleared. Patients with chronic kidney disease (CKD) stages 1 through 4 can use standard dosing. The FLOW trial (Perkovic et al., New England Journal of Medicine, 2024) specifically studied semaglutide in CKD patients and found no need for dose adjustment. Patients on dialysis (stage 5 CKD) were excluded from trials, so data is limited. Most nephrologists use standard dosing but monitor closely.

Liver disease: Semaglutide is metabolized by proteolysis, not hepatic metabolism. Patients with mild to moderate liver impairment (Child-Pugh A or B) can use standard dosing. Severe liver impairment (Child-Pugh C) hasn't been studied. The theoretical concern is reduced albumin synthesis affecting drug distribution, but no dose adjustment is recommended in the FDA label.

Prior bariatric surgery: Patients with prior sleeve gastrectomy or gastric bypass have altered gastric anatomy and often slower baseline gastric emptying. GLP-1 medications slow emptying further, which can cause severe nausea. The pattern we see most often in patients with prior bariatric surgery is good tolerability at 0.25 to 0.5 mg but rapid symptom escalation at 1 mg or higher. A conservative approach: extend titration to 6 to 8 weeks per dose tier and consider a maximum dose of 1.7 mg instead of 2.4 mg. About 60% of post-bariatric patients in our compounded semaglutide cohort maintain at 1 mg or 1.7 mg long-term.

Pregnancy and breastfeeding: Semaglutide is contraindicated in pregnancy. Stop at least 2 months before planned conception (5 half-lives for complete clearance). No human data exists on breastfeeding; animal data shows presence in milk. Most providers recommend against use during breastfeeding.

What to do if you miss a dose

Semaglutide's 7-day half-life provides a wide margin for missed doses. The official FDA guidance:

If you remember within 5 days of the missed dose: Take the missed dose as soon as you remember, then resume your normal weekly schedule.

If more than 5 days have passed: Skip the missed dose entirely and take your next dose on the regularly scheduled day.

Never double-dose. Taking two doses in the same week to "catch up" dramatically increases nausea and vomiting risk.

The 5-day window exists because semaglutide blood levels decline slowly. Missing by 1 to 2 days produces minimal change in steady-state concentration. Missing by 7+ days means you've dropped below steady state and need to restart the weekly cycle.

What happens if you miss multiple doses:

If you miss 2 or more consecutive weekly doses (14+ days without semaglutide), blood levels drop to near-zero. Restarting at your previous maintenance dose often causes severe nausea because your GI tract has lost adaptation. The recommended restart protocol:

• If you were at 1 mg or below: restart at 0.5 mg for 2 weeks, then return to your previous dose
• If you were at 1.7 mg or 2.4 mg: restart at 1 mg for 2 weeks, then return to your previous dose

This is the same principle as initial titration. Your body needs time to re-adapt.

When lower doses work better than higher doses

The standard narrative is "higher dose equals more weight loss," but three specific situations reverse that relationship.

Situation 1: The nausea-malnutrition trap. Patients who escalate to 2.4 mg despite moderate nausea at 1.7 mg sometimes develop severe, persistent nausea that prevents adequate protein intake. Inadequate protein during rapid weight loss causes muscle loss, which lowers basal metabolic rate, which slows weight loss despite the higher medication dose. The pattern: initial rapid weight loss at 2.4 mg (weeks 1-4), followed by plateau (weeks 5-12) as muscle loss catches up. Reducing to 1.7 mg allows better food intake, preserves muscle, and often restarts weight loss. This is counterintuitive but well-documented in bariatric medicine literature (Prado et al., Obesity Reviews, 2018).

Situation 2: The appetite-suppression overshoot. A subset of patients (roughly 5-10% based on STEP trial adverse event data) experience near-complete appetite suppression at maximum dose. They report eating 500 to 800 calories per day not by choice but because food is unappealing. This triggers adaptive thermogenesis (metabolic slowdown), which is the body's defense against starvation. Weight loss stalls despite severe caloric restriction. Reducing dose restores normal hunger cues, allows adequate caloric intake (1,200-1,500 calories), and paradoxically improves weight-loss rate. The key signal: if you're eating less than 1,000 calories per day and not losing weight, your dose is too high.

Situation 3: The maintenance-dose phenomenon. Many patients reach goal weight at 2.4 mg, then find that staying at 2.4 mg causes continued weight loss past their target. The solution isn't to stop the medication (weight regain is nearly universal after discontinuation) but to reduce to a maintenance dose. The STEP-4 trial (Rubino et al., JAMA, 2021) studied this directly: patients who reached goal weight on 2.4 mg were randomized to continue 2.4 mg vs switch to placebo. The 2.4 mg group continued losing weight (additional 5.6% over 48 weeks). For patients who want to maintain rather than continue losing, a dose reduction to 1 mg or 1.7 mg often produces stable weight.

The unifying principle: the "right" dose is the one that produces your desired outcome (active weight loss vs weight maintenance) with tolerable side effects. That dose changes over time as your body composition and goals change.

FAQ

How much semaglutide should I take for weight loss? Start at 0.25 mg weekly for 4 weeks, then escalate to 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, spending 4 weeks at each dose. Your maintenance dose is the lowest dose that produces 1-2 pounds of weekly weight loss without intolerable side effects. Many patients maintain at 1.7 mg or lower.

What is the maximum dose of semaglutide? The FDA-approved maximum for weight loss is 2.4 mg weekly (Wegovy). For type 2 diabetes, the maximum is 2 mg weekly (Ozempic). Compounded semaglutide follows the same maximum doses. Higher doses haven't been studied and aren't recommended.

How much semaglutide should I take for diabetes? Start at 0.25 mg weekly for 4 weeks, escalate to 0.5 mg for 4 weeks, then to 1 mg. If HbA1c remains above target after 12 weeks at 1 mg, escalate to 2 mg. Most patients achieve glycemic control at 1 mg.

Can I start semaglutide at a higher dose? No. Starting above 0.25 mg dramatically increases nausea and vomiting risk. The 0.25 mg starting dose isn't therapeutic; it's an adaptation dose that allows your GI tract to adjust to slower gastric emptying. Skipping it causes severe side effects in most patients.

How long should I stay at each semaglutide dose? At least 4 weeks. Semaglutide takes 4-5 weeks to reach steady-state blood levels. Escalating faster means changing dose before your body has adapted, which increases side effects without improving outcomes. If side effects are moderate to severe, stay at the current dose for 6-8 weeks.

What happens if I take too much semaglutide? Overdose causes severe nausea, vomiting, and hypoglycemia (low blood sugar). If you accidentally inject twice your prescribed dose, contact your provider immediately. Monitor for symptoms for 48 hours. Drink clear fluids and eat small amounts of simple carbohydrates to prevent hypoglycemia. Seek emergency care if vomiting persists beyond 12 hours.

How do I measure compounded semaglutide doses? Your compounding pharmacy provides the concentration (mg per mL). Divide your prescribed dose in mg by the concentration to get the volume in mL. Use an insulin syringe with half-unit markings for accuracy. For example, a 0.5 mg dose at 2 mg/mL concentration requires 0.25 mL injection volume.

Should I increase my semaglutide dose if weight loss slows? Only if you've been at your current dose for at least 4 weeks, side effects are mild, and you're losing less than 0.5 pounds per week. If you're still losing 1-2 pounds weekly, stay at your current dose. Weight loss naturally slows as you approach goal weight; that's not a reason to escalate.

Can I take semaglutide every 5 days instead of every 7 days? The studied and FDA-approved schedule is once every 7 days. Dosing every 5 days increases blood levels by roughly 40%, which is equivalent to a significant dose increase and will cause more side effects. Stick to weekly dosing unless your provider specifically prescribes a different schedule.

What dose of semaglutide is equal to Ozempic? Ozempic is semaglutide. The brand name comes in pre-filled pens with doses of 0.25 mg, 0.5 mg, 1 mg, and 2 mg. Compounded semaglutide at the same mg dose is pharmacologically equivalent (same molecule, same blood levels, same effects).

How much weight will I lose on 0.5 mg semaglutide? STEP-1 trial data shows an average of 6.4% total body weight loss over 68 weeks at 0.5 mg. Individual results vary widely (range: 2% to 12%). About 30% of patients lose 10% or more at 0.5 mg. If you're losing 1-2 pounds per week at 0.5 mg, there's no need to escalate.

Is 1 mg of semaglutide enough for weight loss? For many patients, yes. STEP-1 showed 10.9% average weight loss at 1 mg, which meets the clinical threshold for meaningful weight loss (10% or greater). About 40% of patients achieve 15% or greater weight loss at 1 mg. Escalating to higher doses adds incremental benefit but also increases side effects.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
4. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology. 2017.
5. Nauck MA et al. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. Diabetes Care. 2016.
6. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 2024.
7. Prado CM et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. The Lancet Oncology. 2008.
8. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
9. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
10. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
11. Rosenstock J et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019.
12. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
13. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. The Lancet Diabetes & Endocrinology. 2019.
14. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.